Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This study is recruiting in the United States, in Canada, in the United Kingdom, .... It is testing KarXT for Schizophrenia.
Multiple locations, including Chandler
This study is recruiting in the United States, in Bulgaria, in Croatia, .... It is testing ITI-1284 for Schizophrenia.
Multiple locations, including AnaheimThis study is recruiting in the United States, in France, in Canada, .... It is testing ML-007C-MA for Schizophrenia.
Multiple locations, including PhoenixThis study is recruiting in the United States, in France, in Belgium, .... It is testing KarXT for Schizophrenia.
Multiple locations, including ChandlerThis study is recruiting in the United States. It is testing KYN-5356 for schizophrenia.
Multiple locations, including Little RockThis study is recruiting in the United States, in Australia, in Canada, .... It is testing Safety and Efficacy of KarXT + KarX-EC for Schizophrenia.
Multiple locations, including GilbertThis study is recruiting in the United States. It focuses on Schizophrenia.
Multiple locations, including Little RockThis study is recruiting in the United States. It focuses on adults with tardive dyskinesia who remain symptomatic while receiving or after stopping a VMAT2 inhibitor.
Multiple locations, including BryantThis study is recruiting in the United States, in Argentina, in Colombia, .... It is testing KarXT for schizophrenia.
Multiple locations, including AnaheimThis study is recruiting in Japan. It is testing KarXT for schizophrenia.
Multiple locations, including KōnanThis study is recruiting in the United States, in France, in Canada, .... It is testing KarXT and KarX-EC for schizophrenia.
Multiple locations, including AnaheimThis study is recruiting in the United States. It focuses on Schizophrenia.
Multiple locations, including Los AlamitosHopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.